Eastwood Bio-Medical Canada Inc (EBM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eastwood Bio-Medical Canada Inc (EBM) has a cash flow conversion efficiency ratio of 0.001x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-900.00 ≈ $-651.05 USD) by net assets (CA$-1.65 Million ≈ $-1.19 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Eastwood Bio-Medical Canada Inc to measure how much of total assets are equity-financed.
Eastwood Bio-Medical Canada Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Eastwood Bio-Medical Canada Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Eastwood Bio-Medical Canada Inc (EBM) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Eastwood Bio-Medical Canada Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eastwood Bio-Medical Canada Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Metagenomi, Inc. Common Stock
NASDAQ:MGX
|
-0.154x |
|
YeaRimDang Publishing Co. Ltd
KQ:036000
|
-0.069x |
|
PanGen Biotech Inc
KQ:222110
|
-0.122x |
|
Me2on Co. Ltd
KQ:201490
|
0.027x |
|
Libental
TA:LBTL
|
-2.455x |
|
ICD Co. Ltd
KQ:040910
|
-0.043x |
|
Metalpha Technology Holding Limited
NASDAQ:MATH
|
0.310x |
|
Pacgold Ltd
AU:PGO
|
-0.032x |
Annual Cash Flow Conversion Efficiency for Eastwood Bio-Medical Canada Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Eastwood Bio-Medical Canada Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see EBM stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-10-31 | CA$-1.63 Million ≈ $-1.18 Million |
CA$19.30K ≈ $13.96K |
-0.012x | -200.95% |
| 2024-10-31 | CA$-1.30 Million ≈ $-937.99K |
CA$-15.22K ≈ $-11.01K |
0.012x | -41.57% |
| 2023-10-31 | CA$-840.80K ≈ $-608.22K |
CA$-16.89K ≈ $-12.22K |
0.020x | +37.61% |
| 2022-10-31 | CA$-294.20K ≈ $-212.82K |
CA$-4.29K ≈ $-3.11K |
0.015x | -98.19% |
| 2021-10-31 | CA$-144.32K ≈ $-104.40K |
CA$-116.21K ≈ $-84.07K |
0.805x | +168.15% |
| 2020-10-31 | CA$459.27K ≈ $332.23K |
CA$-542.69K ≈ $-392.58K |
-1.182x | -770.13% |
| 2019-10-31 | CA$1.31 Million ≈ $948.87K |
CA$-178.13K ≈ $-128.86K |
-0.136x | +43.59% |
| 2018-10-31 | CA$1.89 Million ≈ $1.37 Million |
CA$-454.79K ≈ $-328.99K |
-0.241x | -87.18% |
| 2017-10-31 | CA$2.76 Million ≈ $2.00 Million |
CA$-355.28K ≈ $-257.00K |
-0.129x | -34.57% |
| 2016-10-31 | CA$3.21 Million ≈ $2.32 Million |
CA$-306.58K ≈ $-221.77K |
-0.096x | -31.67% |
| 2015-10-31 | CA$3.73 Million ≈ $2.70 Million |
CA$-270.51K ≈ $-195.68K |
-0.073x | -118.34% |
| 2014-10-31 | CA$3.99 Million ≈ $2.88 Million |
CA$1.58 Million ≈ $1.14 Million |
0.396x | -67.40% |
| 2013-10-31 | CA$-208.29K ≈ $-150.68K |
CA$-252.88K ≈ $-182.93K |
1.214x | -- |
About Eastwood Bio-Medical Canada Inc
Eastwood Bio-Medical Canada Inc. markets, develops research, and distributes natural health products under the Eleotin brand in Canada, the United States, and Asia. The company distributes Eleotin, which provides natural remedies for metabolic disorders, such as blood glucose disorders, hypertension, and obesity. It also offers Eleotin A 700 for the treatment for spleen deficiency, lack of appeti… Read more